Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
- Associated Therapies
- -
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
- First Posted Date
- 2004-08-18
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Our Lady of Mercy Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00003885
- Locations
- 🇺🇸
Our Lady of Mercy Medical Center, Bronx, New York, United States
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
- Conditions
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003395
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003630
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Oncotherapeutics
- Registration Number
- NCT00085345
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States
🇺🇸Utah Cancer Specialists - Administrative Office, Salt Lake City, Utah, United States
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005069
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
- Conditions
- Interventions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT00006220
- Locations
- 🇺🇸
Washington University Barnard Cancer Center, Saint Louis, Missouri, United States
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005040
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00081133
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005618
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00006090
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.